NCT04208412 - A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

December 8, 2020

Study Completion Date

December 8, 2020

Conditions

Hereditary Angioedema

Interventions

DRUG

KVD900

KVD900 tablet 600 mg

OTHER

Placebo

KVD900-matched Placebo Tablet

Trial Locations (25)

1

KalVista Investigative Site, Milan

20815

KalVista Investigative Site, Chevy Chase

45231

KalVista Investigative Site, Cincinnati

75231

KalVista Investigative Site, Dallas

80112

KalVista Investigative Site, Centennial

85251

KalVista Investigative Site, Scottsdale

99204

KalVista Investigative Site, Spokane

Unknown

KalVista Investigative Site, Vienna

KalVista Investigative Site, Brno

KalVista Investigative Site, Hradec Králové

KalVista Investigative Site, Pilsen

KalVista Investigative Site, Berlin

KalVista Investigative Site, Frankfurt

KalVista Investigative Site, Mörfelden-Walldorf

KalVista Investigative Site, Budapest

KalVista Investigative Site, Milano-2

KalVista Investigative Site, Padua

KalVista Investigative Site, Amsterdam

KalVista Investigative Site, Skopje

KalVista Investigative Site, Krakow

KalVista Investigative Site, Warsaw

KalVista Investigative Site, Camberley

KalVista Investigative Site, Cambridge

KalVista Investigative Site, London

KalVista Investigative Site, Newcastle